Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes-Reference-Cited by-同舟云学术

Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes

Published:2022-03-22 Issue:5 Volume:130 Page:592-605
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharma Tox

Author:

Jin Zhiping¹²,He Qingfeng¹^ORCID,Zhu Xiao¹,Zhu Mingshe³,Wang Yike⁴,Wu Xin‐an⁵,Lv Qianzhou²,Xiang Xiaoqiang¹^ORCID

Affiliation:

1. Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai China

2. Department of Clinical Pharmacy Zhongshan Hospital, Fudan University Shanghai China

3. MassDefect Technologies Princeton NJ USA

4. College of Pharmacy University of Nebraska Medical Center Omaha NE USA

5. Department of Pharmacy The First Hospital of Lanzhou University Lanzhou China

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13721

Reference43 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

2. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically Based Pharmacokinetic Modeling and Clinical Extrapolation for Topical Application of Pilocarpine on Eyelids: A Comprehensive Study;Journal of Pharmaceutical Sciences;2024-09

2. Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges;Clinical Pharmacokinetics;2024-06-18

3. Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: Studied from pharmacokinetic and pharmacodynamic perspectives;European Journal of Pharmaceutical Sciences;2023-09

4. Prediction of Drug–Drug Interactions with Ensartinib as a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model;Drug Metabolism and Disposition;2023-08-29

5. Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer;Frontiers in Oncology;2023-03-03